ENTERA BIO LTD (ENTX) Stock Price, Forecast & Analysis

NASDAQ:ENTX • IL0011429839

1.4 USD
-0.02 (-1.41%)
At close: Feb 18, 2026
1.62 USD
+0.22 (+15.71%)
After Hours: 2/18/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

ENTX Key Statistics, Chart & Performance

Key Statistics
Market Cap64.20M
Revenue(TTM)124.00K
Net Income(TTM)-10.78M
Shares45.86M
Float34.60M
52 Week High3.22
52 Week Low1
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.13
PEN/A
Fwd PEN/A
Earnings (Next)03-26
IPO2018-06-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
ENTX short term performance overview.The bars show the price performance of ENTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30 -40

ENTX long term performance overview.The bars show the price performance of ENTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40

The current stock price of ENTX is 1.4 USD. In the past month the price decreased by -10.83%. In the past year, price decreased by -33.33%.

ENTERA BIO LTD / ENTX Daily stock chart

ENTX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
ENTX Full Technical Analysis Report

ENTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ENTX. While ENTX has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ENTX Full Fundamental Analysis Report

ENTX Financial Highlights

Over the last trailing twelve months ENTX reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 50% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -61.93%
ROE -70.77%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%12.5%
Sales Q2Q%-100%
EPS 1Y (TTM)50%
Revenue 1Y (TTM)N/A
ENTX financials

ENTX Forecast & Estimates

7 analysts have analysed ENTX and the average price target is 10.2 USD. This implies a price increase of 628.57% is expected in the next year compared to the current price of 1.4.

For the next year, analysts expect an EPS growth of -14.24% and a revenue growth -69.78% for ENTX


Analysts
Analysts82.86
Price Target10.2 (628.57%)
EPS Next Y-14.24%
Revenue Next Year-69.78%
ENTX Analyst EstimatesENTX Analyst Ratings

ENTX Ownership

Ownership
Inst Owners19.74%
Ins Owners2.41%
Short Float %0.3%
Short Ratio0.46
ENTX Ownership

ENTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.75411.552B
AMGN AMGEN INC16.85201.047B
GILD GILEAD SCIENCES INC17.12192.64B
VRTX VERTEX PHARMACEUTICALS INC23.07121.106B
REGN REGENERON PHARMACEUTICALS17.0583.892B
ALNY ALNYLAM PHARMACEUTICALS INC49.6643.941B
INSM INSMED INC N/A32.101B
NTRA NATERA INC N/A29.393B
BIIB BIOGEN INC12.7628.709B
UTHR UNITED THERAPEUTICS CORP16.1520.773B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About ENTX

Company Profile

ENTX logo image Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Company Info

ENTERA BIO LTD

Hadassah / Jerusalem Bio, Park, 5th Floor

JERUSALEM 9112002 IL

CEO: Spiros Jamas

Employees: 19

ENTX Company Website

ENTX Investor Relations

Phone: 97225327151

ENTERA BIO LTD / ENTX FAQ

What does ENTX do?

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.


Can you provide the latest stock price for ENTERA BIO LTD?

The current stock price of ENTX is 1.4 USD. The price decreased by -1.41% in the last trading session.


Does ENTERA BIO LTD pay dividends?

ENTX does not pay a dividend.


What is the ChartMill technical and fundamental rating of ENTX stock?

ENTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the Price/Earnings (PE) ratio of ENTERA BIO LTD (ENTX)?

ENTERA BIO LTD (ENTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).


What is the market capitalization of ENTX stock?

ENTERA BIO LTD (ENTX) has a market capitalization of 64.20M USD. This makes ENTX a Micro Cap stock.


What is the next earnings date for ENTX stock?

ENTERA BIO LTD (ENTX) will report earnings on 2026-03-26, after the market close.